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ABSTRACT: A multidisciplinary strategy, including both
biochemical and biophysical studies, was proposed here to
evaluate the potential of lipid nanoaggregates consisting of a
mixture of a gemini−bolaamphiphilic lipid (C6C22C6) and the
well-known helper lipid 1,2-dioleoyl-sn-glycero-3-phosphatidy-
lethanolamine (DOPE) to transfect plasmid DNA into living
cells in an efficient and safe way. For that purpose, several
experimental techniques were employed, such as zeta potential
(phase analysis light scattering methodology), agarose gel
electrophoresis (pDNA compaction and pDNA protection
assays), small-angle X-ray scattering, cryo-transmission electron
microscopy, atomic force microscopy, fluorescence-assisted cell
sorting, luminometry, and cytotoxicity assays. The results
revealed that the cationic lipid and plasmid offer only 70 and
30% of their nominal positive ( = ++q 2.0nom,C C C6 22 6 ) and negative charges ( = −
−q 2/bpnom,pDNA ), respectively. Upon mixing with
DOPE, they form lipoplexes that self-aggregate in typical multilamellar Lα lyotropic liquid-crystal nanostructures with sizes in the
range of 100−200 nm and low polydispersities, very suitably fitted to remain in the bloodstream and cross the cell membrane.
Interestingly, these nanoaggregates were able to compact, protect (from the degrading effect of DNase I), and transfect two DNA
plasmids (pEGFP-C3, encoding the green fluorescent protein, and pCMV-Luc, encoding luciferase) into COS-7 cells, with an
efficiency equal or even superior to that of the universal control Lipo2000*, as long as the effective +/− charge ratio was
maintained higher than 1 but reasonably close to electroneutrality. Moreover, this transfection process was not cytotoxic because
the viability of COS-7 cells remained at high levels, greater than 80%. All of these features make the C6C22C6/DOPE nanosystem
an optimal nonviral gene nanocarrier in vitro and a potentially interesting candidate for future in vivo experiments.
■ INTRODUCTION
Nucleic acids are nowadays an attractive source of therapeutic
agents because of their intimate structure−activity relationships
and their highly specific mode of action, allowing exploitation
of the cellular machinery in a predictable fashion to either
stimulate or silence the expression of virtually any protein, with
reduced toxicity and lessened side effects.1−4 These aspects are
the basis of gene therapy, an exciting branch of medicine that
aims to cure diseases at a molecular level by either repairing
damaged cellular DNA5−7 or silencing the expression of
abnormal genes.8−10 In the case of biomolecular drugs such
as nucleic acids, the carrier becomes a decisive protagonist,
allowing the drug to overcome the physiological barriers and
reach its target in a fully functional form to carry out the
designed therapeutic function, given that nucleic acids are easily
degraded by nucleases in biological fluids and their membrane-
crossing abilities and cellular uptake are seriously limited by
their inherently large size, rigidity, and negative charge.11,12
Gene carriers or gene vectors are usually classified into two
groups: viral and nonviral. Although viral gene vectors are
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normally more effective, they may cause serious adverse effects
in the organism.13−15 Accordingly, researchers have mostly
focused their efforts on the development of nonviral carriers
capable of compacting, protecting, and transporting genetic
materials in an efficient and safe way by combining high
transfection efficiencies (TEs) with low cytotoxicity out-
puts.6,16−21
Among the nonviral gene vectors available, a wide series of
gemini cationic lipids (GCLs), constituted by two hydrophobic
chains and two hydrophilic cationic heads linked by a spacer,
have proven in the last decade their capacity to compact,
protect, and release DNA in the cytoplasm of living cells.6,22−24
Together with these GCLs, another class of lipids, known as
bolaform or bolaamphiphilic (BA) lipids characterized by
bearing two hydrophilic (ionic or nonionic) heads separated by
one, two, or three long hydrophobic spacers (usually alkyl
chains of 22−32 carbon atoms), have also exhibited potential as
gene vectors.25−29 Their peculiar structure means that, in
general terms, they tend to self-aggregate, forming monolayer-
type membranes with less permeability, greater rigidity, and
better durability than the lipid bilayer-type membranes typically
formed from gemini lipids. In fact, BA lipids have already been
successfully used as nonviral gene vectors in cases where at least
one or both heads are positively charged.30−41
In this work, we have evaluated the potential of a so-called
gemini−bolaamphiphilic (GBA) lipid as a novel gene vector.
The GBA lipid was synthesized with a hybrid structure between
that of a gemini lipid (GCL), insofar it contains two secondary
amine-type cation heads each of them attached to short
hydrophobic chains of 6 carbon atoms, and that of a BA lipid in
the sense that the cationic heads are connected by a long spacer
of 22 carbon atoms (referred to as C6C22C6, Scheme 1). The
disproportion between the short length of the hydrophobic
chains (6C) and that of the long spacer (22C) results in the
latter, potentially playing a leading role first in the self-
aggregation process and then in the formation of the lipoplex in
the presence of DNA. As usual, with this type of nanocarrier,
the cationic lipid was mixed with 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine (DOPE), a well-known fusogenic
and helper lipid that promotes cellular uptake.42−44 The
C6C22C6/DOPE mixed lipid vector was used in this work to
compact and transfect two DNA plasmids into COS-7 cells:
one encoding the green fluorescent protein (GFP) (pEGFP-
C3) and the other one encoding luciferase (pCMV-Luc).
Accompanying this biochemical evaluation of the TE
(fluorescence-assisted cell sorting (FACS) and luminometry)
and cytotoxicity (alamarBlue assay), a biophysical study is
included, comprising the size [dynamic light scattering (DLS)],
structural [cryo-transmission electronic microscopy (cryo-
TEM), small-angle X-ray scattering (SAXS), and atomic force
microscopy (AFM)], and electrochemical (zeta potential and
gel electrophoresis) characterizations of the optimal composi-
tions of C6C22C6/DOPE−pDNA lipoplexes, as previously
determined from their biochemical performance.
■ RESULTS AND DISCUSSION
Multidisciplinary and complementary biophysical and bio-
chemical studies, as those reported herein, are needed to assess,
with a wider perspective, the ability of a given nanosystem to
compact, protect, transport across cell membranes and deliver
the nucleic acids into the cell interior, overcoming the
physiological barriers that the nanocarrier−DNA complex
may find along such a remarkable journey.
The electrochemical evaluation of the C6C22C6/DOPE−
pDNA system, consisting of electrophoretic mobility/zeta
potential and agarose gel electrophoresis assays (compaction
and protection of pDNA against degradation by DNase I), is
shown in Figures 1 and 2 at different molar compositions of the
cationic lipid in the mixed lipid (α). These three experiments
allowed us to (i) check whether the vector was capable of
compacting pDNA and at what lipoplex compositions this
compaction would occur (inset in Figure 1); (ii) accurately
determine the electroneutrality of the system and thus the
effective charges of both cationic GBA lipid and plasmid DNA
(Figure 1); and (iii) confirm that the nanocarrier is able to
protect adequately the plasmid against the degrading effect of
DNase I (Figure 2). The inset in Figure 1 reports an agarose gel
electrophoresis experiment, where pDNA was loaded as a
control in the first lane of the gel and C6C22C6/DOPE−pDNA
lipoplexes at different mass ratios (mL/mDNA = (mL+ + mL0)/
mDNA, where mL+, mL0, and mDNA denote the masses of the
cationic gemini lipid, zwitterionic helper lipid, and nucleic acid,
Scheme 1. Schematic Drawings of a GCL, a Cationic BA
lipid, and the Resulting Hybrid Structure, that is, the
Cationic GBA lipid Proposed and Synthesized in This Work
and detailed structure of the C6C22C6 GBA lipid
Figure 1. Plot of zeta potential as a function of mL/mDNA mass ratio of
the C6C22C6/DOPE−DNA lipoplexes, constituted by ctDNA at
several molar compositions of the cationic lipid in the mixed lipids
(α = 0.5, pink line) and with pDNA at α = 0.2, 0.5, and 0.7 (blue, red,
and black lines), respectively. Inset: agarose gel electrophoresis of
C6C22C6/DOPE−pDNA at several mL/mDNA mass ratios and α = 0.5.
Free pDNA (lane 1) was used as the control.
ACS Omega Article
DOI: 10.1021/acsomega.7b01657
ACS Omega 2018, 3, 208−217
209
respectively) were loaded in lanes 2−4. The two fluorescence
bands observed in lane 1 are characteristic of the coiled and
supercoiled forms of plasmid DNA, whereas the absence of
such bands in lanes 2−4, together with the fact that pDNA
remains immobile in the well of the gel, is a clear indication of
the effective compaction of pDNA by the C6C22C6/DOPE lipid
vector. In particular, at α = 0.5, compaction is already achieved
at a mass ratio of mL/mDNA = 0.8. Additionally, this indicates
that electroneutrality in this lipoplex must be reached at
compositions below 0.8 when α = 0.5. Figure 1 also shows the
plot of zeta potential versus mL/mDNA, displaying a typical
sigmoidal profile at different molar compositions. From the
electroneutrality ratios, (mL/mDNA)ϕ, that is, the mL/mDNA
ratios at which charge compensation occurs and the zeta
potential is zero, the effective charges of C6C22C6
( = ±+q 1.4 0.1eff,C C C6 22 6 ) and pDNA ( = ±
−q 0.6 0.1eff,pDNA )
were calculated by a procedure developed by us and fully
described elsewhere.45,46 The cationic lipid and plasmid were
found to exhibit only 70 and 30% of their nominal positive
( =+q 2.0nom,C C C6 22 6 ) and negat ive ( = −
−q 2/bpnom,pDNA )
charges, respectively, which is a behavior typically observed in
this type of systems.46−48 It is well-known that plasmids in
supercoiled conformation are able to retain a significant amount
of Na+ cations under physiological conditions, ostensibly
reducing their anionic character. This fact may be advantageous
for our objectives because the lower the anionic character of the
plasmid, the smaller the amount of cationic vector necessary to
compact it and yield a net positive charge (necessary to cross
the also negatively charged cell membrane), thus reducing the
overall cytotoxicity of the nanocarrier. Such understanding of
the effective charges allowed us to work with effective charge













eff,DNA DNA DNA/bp (1)
For a nanosystem to become a suitable gene vector, in
addition to being able to efficiently compact the plasmid and
generate a purely cationic entity, the system must be capable of
protecting the nucleic acid against the degrading effect of the
DNases present in human serum. This information is crucial
when attempting to carry out in vivo studies. As can be seen in
Figure 2, where the protection experiments against DNase I are
presented, the mixed lipid system C6C22C6/DOPE efficiently
Figure 2. Protection assay of pDNA against degradation by DNase I
(gel electrophoresis experiment): (a) pCMV-Luc plasmid, (b)
pEGFP-C3 plasmid, and (c) a visual guide. In both experiments:
lane 1, pDNA; lane 2, pDNA−DNase I; and lanes 3−6, C6C22C6/
DOPE−pDNA lipoplexes at different molar compositions of the
cationic lipid in the mixed lipids (α = 0.2 in lanes 3−4 and α = 0.5 in
lanes 5−6) and different effective charge ratios of the lipoplex, ρeff = 4
(lanes 3 and 5) and ρeff = 10 (lanes 4 and 6).
Figure 3. TE levels of C6C22C6/DOPE−pDNA lipoplexes in COS-7 cells at two molar compositions of the cationic lipid in the mixed lipids (α = 0.2
and 0.5): (a) expressed as % GFP (solid bars) and MFI (squared bars) for plasmid pEGFP-C3 and (b) expressed as nanograms of luciferase per
milligrams of protein for plasmid pCMV-Luc. The experiments were performed in the presence of 10% serum (FBS). The orange and green bars
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protects the two plasmids used in this work, one encoding the
GFP (pEGFP-C3) and the other one encoding luciferase
(pCMV-Luc). Thus, lane 1 (naked pDNA) shows the
characteristic fluorescence bands from the emission of ethidium
bromide (EtBr) intercalated within the double helix of the
plasmid DNA in its coiled and supercoiled forms, whereas lane
2 reflects the progress of the free plasmid along the gel in the
absence of a vector after digestion treatment with DNase I.
C6C22C6/DOPE−pDNA lipoplexes at different compositions
and effective charge ratios were loaded in lanes 3−6 after
digestion with DNase I and subsequent treatment with an
anionic surfactant [Sodium dodecyl sulfate (SDS)], breaking
the lipoplexes and freeing the plasmid. The absence of
fluorescence bands in lane 2 and their presence in lanes 3−6
in both gels (Figure 2a,b) demonstrate that DNase I degraded
the free plasmid in lane 2 but it did not have access to the
plasmid compacted by the vector C6C22C6/DOPE at any of the
studied cationic molar compositions of the mixed lipid (α = 0.2
and 0.5) and effective charge ratios (ρeff = 4 and 10).
These observations allow us to conclude that the C6C22C6/
DOPE lipidic system shows the required features to be, at least
potentially, a suitable nonviral gene vector, given that it is
capable of compacting, protecting from DNases, and trans-
porting pDNA through the cell membrane into the cytoplasm.
To verify whether this process could actually be carried out
efficiently and safely, transfection experiments and cell viability
assays were performed on COS-7 cells in the presence of 10%
serum. Figure 3 shows the TE by means of the expression levels
of (a) GFP (for plasmid pEGFP-C3), given in terms of % GFP
(percentage of cells expressing GFP) and/or MFI (mean
fluorescence intensity per cell) obtained from FACS experi-
ments, and (b) luciferase (for plasmid pCMV-Luc), expressed
in terms of nanograms of luciferase/milligrams of protein, as
obtained from luminometry experiments. In both cases, the
experiments were performed at two molar compositions of the
mixed lipids, α = 0.2 and 0.5, and at two different effective
charge ratios of the lipoplex, ρeff = 4 and 10, using
Lipofectamine 2000 (Lipo2000*) as a positive control. Overall,
the results presented in Figure 3a for plasmid pEGFP-C3
indicate that the TE levels are superior at ρeff = 4 to those at ρeff
= 10, both at α = 0.2 and 0.5. In particular, the values of % GFP
and MFI at ρeff = 4 and α = 0.2 or 0.5 are comparable to or
even slightly higher than those with Lipo2000*, whereas at ρeff
= 10, they are equal to or slightly lower than those of the
control. On the other hand, Figure 3b shows that in the case of
plasmid pCMV-Luc, there is a clear superiority in the
nanograms of luciferase expressed per milligrams of protein
obtained at ρeff = 4 than that at ρeff = 10 at the two α values
studied, the levels of TE being comparable to those of the
control only at α = 0.5.
Gene therapy protocols require vectors not only to be
efficient for the compaction, protection, transport, and delivery
of plasmids inside the cell but also to perform these functions in
a safe way. In this regard, the cytotoxicity of C6C22C6/DOPE−
pDNA lipoplexes in COS-7 cells was evaluated by the
alamarBlue assay at the same molar compositions and effective
charge ratios used in the cell transfection experiments. Figure 4
reports the results obtained with the plasmids pEGFP-C3 and
pCMV-Luc. Viability percentages above 60% were assumed to
be reasonably acceptable, with values over 80% being the most
desired. It is worth noting that the obtained cell viability levels
are above 80% in both cases for ρeff = 4 at both molar ratios of
α = 0.2 and 0.5. However, at ρeff = 10, the viability clearly falls
below 80% and in one case even below 60%. Note that the cell
viability of the Lipo2000* control is around 90%; therefore, it
can be concluded that the nanovector used presents cellular
viabilities comparable to those of the control only at the
effective charge ratio of ρeff = 4. These results are consistent
with other previously reported results48,49 and suggest that the
viability of the cells is seriously compromised at high ρeff values,
that is, at high cationic lipid contents, as one would expect.
So as to correlate the cellular activity and viability results with
the structural characteristics of the studied lipoplexes, several
key factors, such as the size, structure, morphology, and
pDNA−mixed lipid interactions, were evaluated. For that
purpose, DLS, SAXS, cryo-TEM, and AFM experiments were
performed at the optimum effective charge ratio determined in
the biochemical study (ρeff = 4) and at different compositions
of the mixed lipid system. Table S1 in the Supporting
Information summarizes the size (hydrodynamic diameter,
Dh) and polydispersity (PDI) values for the C6C22C6/DOPE−
pDNA lipoplexes at α = 0.2 and 0.5. The obtained sizes (in the
range of 100−200 nm) and reasonably good homogeneity (low
polydispersities of 0.2−0.3) are in the optimal range to cross
Figure 4. Cell viability of COS-7 cells in the presence of C6C22C6/DOPE−pDNA lipoplexes at two molar compositions of the cationic lipid in the
mixed lipids (α = 0.2 and 0.5). The plasmids used were (a) pEGFP-C3 and (b) pCMV-Luc. The experiments were performed with 10% serum
(FBS). The orange and green bars correspond to the effective charge ratios of ρeff = 4 and 10 in the lipoplex, respectively. The gray bar corresponds
to Lipo2000*, used here as the positive control. The results were normalized to those obtained for untreated cells (100%).
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the cell membrane and circulate in the bloodstream, making
these lipoplexes potentially suitable DNA nanocarriers. No
significant effect of the cationic lipid molar composition in the
mixed lipid or of the effective charge ratio in the lipoplexes was
observed on neither of these two parameters.
Figure 5 summarizes the results of cryo-TEM (panels a and
b) and SAXS (panel c) experiments at ρeff = 4 and different
molar compositions (α). Both experimental techniques
revealed that these lipoplexes self-organize in multilamellar Lα
phases of lyotropic liquid crystals, as previously reported for
other mixed lipid-type nonviral gene vectors.49−51 Notice the
presence of clear fingerprint patterns (indicated with a white
point in the micrographs of panels a and b) regardless of the
composition α in the mixed lipid system. The periodic
repetition of lipid layers was studied by fast Fourier transform
(FFT) analysis on certain zones of the micrographs (the yellow
square in Figure 5a), where patterns of multilamellar stacking
were found. The inset in Figure 5a shows, as an example, a FFT
profile whose diffraction spots are typical of a lamellar structure.
Additionally, the Bragg maxima reported in the SAXS
diffractograms (Figure 5c) match adequately the hkl Miller
indexes characteristic of multilamellar Lα structures, consisting
of alternating layers of mixed lipids and supercoiled plasmid
DNA in a sandwich-type fashion (see the scheme in Figure 5d),
in total agreement with the cryo-TEM images. The interlayer
distance (d) related to the q factor of the first maximum (d =
2π/q100) has an average value of 5.3 ± 0.3 nm, being not
appreciably influenced by the composition of the mixed lipid
system (α) within experimental error (Figure 5e). This
distance, clearly shorter than the typical one (∼7 nm) found
in other systems composed of gemini cationic/DOPE lipid
mixtures,45,51 can be expressed as the sum of two thicknesses:
that of the region where the hydrophobic chains of the lipids
self-aggregate, traditionally denoted as dm, plus that of the
aqueous region where the plasmid DNA is located, known as
dw. Given the particular structure of the cationic lipid used
(C6C22C6), two alternative arrangements can be proposed for
the mixed lipid layer, both compatible with the SAXS results.
The first one is a lipidic layer consisting of C6C22C6 cationic
lipid molecules organized in a monolayer fashion mixed with
DOPE helper lipid molecules in a bilayer disposition. In this
case, the length of the C22 spacer of C6C22C6 determines the
thickness of the monolayer, with the two hydrophobic C6 alkyl
chains oriented inwardly with the two cationic quaternary
ammonium heads exposed to both sides of the monolayer. This
arrangement necessarily imposes an important interpenetration
(of around seven methylene groups) of the hydrophobic chains
of DOPE (18 carbon atoms) so that the system can self-
organize in a bilayer fashion, matching well the d value of 5.3
nm imposed by the spacer length of the cationic GBA lipid.
The second arrangement is the typical lipid bilayer consisting of
a mixture of C6C22C6 and the DOPE helper lipid. In this case,
the 22-carbon-atom spacer linking the cationic heads of
C6C22C6 is forced to bend inwardly in a V-shaped manner so
as to accommodate itself in the bilayer and the DOPE chains
have to necessarily overlap extensively to fit the interlayer
distance (5.3 nm) obtained from the diffractograms. Figure 6
shows a simplified 2D view of the Lα structure exhibited by
these lipoplexes, with the two options discussed above. In both
cases, either as a monolayer (Figure 6a) or as a lipid bilayer
(Figure 6b), the thickness according to the Tanford’s model52
was estimated to be dm ≈ 3.0 nm, which would lead to a dw
value of ca. 2.3 nm, which is enough to host the plasmid DNA.
Several features can be highlighted: (i) both self-organization
structures are compatible with the experimental thickness of d =
5.3 ± 0.3 nm and with the observation that d is not influenced
by the DOPE content (Figure 5e); (ii) both arrangements have
been previously reported for bolaform lipid systems27−29,33 and
derived gemini cationic/DOPE lipid systems;45,47,51 and (iii)
both arrangements provide an explanation of why the thickness
Figure 5. (a,b) Cryo-TEM micrographs of C6C22C6/DOPE−pDNA lipoplexes at ρeff = 4 and molar compositions of the cationic lipid in the mixed
lipids of (a) α = 0.2 and (b) α = 0.5. The inset in (a) shows the diffraction spot from the FFT calculations over the selected area on the original
micrograph. The white points indicate the lamellar structure with a multilamellar pattern. The scale bar is 200 nm. (c) SAXS diffractograms of
C6C22C6/DOPE−pDNA lipoplexes at an effective charge ratio of ρeff = 4 and different molar compositions (α). (d) Three-dimensional scheme of
the Lα multilamellar lyotropic liquid-crystal structure. (e) Plot of interlamellar distance (d) of this Lα multilamellar structure as a function of molar
composition of the mixed lipids (α) at ρeff = 4.
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of the lipid layer (d) is notably lower than that found in other
GCL/DOPE mixed lipid systems forming a bilayer with no
interpenetration of the lipid hydrophobic alkyl chains. Although
the apparent lack of influence of the DOPE content on d
confers the same weight to both structural options, the
monolayer arrangement seems more feasible from a molecular
interaction point of view, although further experiments would
be necessary to confirm this.
Undoubtedly, the way pDNA interacts with lipidic
membranes is another important factor affecting the efficiency
of the transfection process. AFM is known to be one of the
techniques of choice to visualize these interactions. Accord-
ingly, AFM experiments were performed for C6C22C6/DOPE
samples (at α = 0.2 and 0.5) in the absence and presence of
pDNA at ρeff = 4 and several incubation times (Figure 7). In
Figure 7a, the topographic image of a supported lipid bilayer
(SLB) of C6C22C6/DOPE at α = 0.2 is shown. The SLB does
not fully cover the mica surface and exhibits a number of holes
of ≥200 nm size (shown in red in the image). Such holes
allowed us to deduce the thickness of the layer, showing a step
height of 4.4 ± 0.4 nm from the mica surface to the top of the
lipid layer. It is possible to observe nonadsorbed lipid structures
as small yellow-white spikes. Upon injection of pDNA, no
significant modification of the shape of the structures was
observed at 60 min. After 180 min, although the margins of the
holes remained almost unmodified, some aggregates were
deposited on the SLB, as observed in the middle right region as
white scratching marks. A different behavior was observed for
the C6C22C6/DOPE SLB at α = 0.5. Figure 7b depicts the
topographic image of this SLB, showing a structure similar to
that in Figure 7a. In this case, the holes present a similar step
height than before (4.6 ± 0.4 nm), but wider holes of 1 or 2 μm
are observed. The mica surface in these wider holes is not flat
but contains some small lipid aggregates on it. Upon injection
of pDNA, some aggregates can be observed inside the wider
holes but not on the lipid layer. This fact suggests that these
aggregates are weakly attached to the lipid surface, thus possibly
being swept away during scanning. This effect is visible up to 60
min of incubation with no significant changes on the edges of
Figure 6. Schematic drawings of the cationic GBA lipid (C6C22C6),
zwitterionic helper lipid (DOPE), and plasmid pDNAs (pEGFP-C3 or
pCMV-Luc) self-organized in a Lα multilamellar lyotropic liquid-
crystal structure. The inset at the bottom of the figure shows a
magnified view of the yellow squared zone of the lipoplex, with two
possible arrangements compatible with the SAXS and cryo-TEM
results: (a) the 22C spacer of C6C22C6 forms a lipid monolayer and
(b) C6C22C6 is organized in a typical lipid bilayer, with the spacer
oriented inward and the bilayer with a V shape. In both cases, DOPE is
organized in a lipid bilayer fashion, with the hydrophobic chains
displaying extensive overlapping to fit the dimensions determined for
the interlamellar distance (d).
Figure 7. Topographic AFM images of the C6C22C6/DOPE SLB in the absence (t = 0 min) and presence of pDNA at ρeff = 4 and molar
compositions of the cationic lipid in the mixed lipids of (a) α = 0.2 and (b) α = 0.5. The Z scale bar is 20 nm.
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the small holes. After 180 min of incubation, the small holes
become slightly wider and, in some regions, they merge to form
wider structures. Such a different behavior of pDNA with lipid
membranes suggests specific interactions of pDNA depending
on the α value. The AFM studies revealed that pDNA modifies
the SLB morphology in a more effective manner at α = 0.5 than
at α = 0.2. Apparently, when pDNA molecules interact with the
SLB at α = 0.5, a reduction of the lateral pressure between the
lipids is observed, promoting the arrangement of the lipids into
an SLB, even when the lipids are adsorbed on a solid surface
such as the mica surface. This fact is evident for the
rearrangement of the lipids in the SLB, that is, the fusion of
holes, without solubilization of part of the SLB. When pDNA
interacts with the SLB at α = 0.2, this effect is less evident. All
of these findings allow us to conclude the following. First,
pDNA molecules seem to be more shielded by mixed lipids
when the amount of the GBA lipid is moderate. This feature
correlates well with the enhanced protection of the plasmid
from the degrading action of the DNase I enzyme, as pointed
by the more intense fluorescence detected in the gels at α = 0.5
compared to that observed at α = 0.2 (Figure 2). Second, the
pDNA molecules reduce the interface tension of the lipids
more effectively at moderate lipid compositions, thus favoring
more deformable lipid membranes. This feature, together with
a larger accumulation of positive charges at α = 0.5, may
promote the formation of multilayer structures, in agreement
with the SAXS and cryo-TEM results (Figure 5) and also with
the higher hydrodynamic sizes found for the lipoplexes at α =
0.5 than at α = 0.2 (see Table S1 in the Supporting
Information). Finally, the pDNA−mixed lipid nanostructures
seem to experience enhanced mobility at moderate lipid
compositions, which may, in turn, favor the efficiency of the
transfection process. This feature correlates well the slightly
better TEs observed for lipoplexes at α = 0.5 compared to those
at α = 0.2 (Figure 3).
■ CONCLUSIONS
It can therefore be concluded that the cationic lipid C6C22C6
(with a hybrid structure between those of a gemini lipid and a
BA lipid) mixed with DOPE and a plasmid DNA forms
lipoplexes displaying a multilamellar nanostructure (Lα) with
sizes in the range of 100−200 nm and low polydispersities, very
suitable for its durability in the bloodstream (a key property for
in vivo studies) and to cross the cell membrane (very important
in transfection processes). The ability of the C6C22C6/DOPE
nanosystem to compact, protect (from the degrading effect of
DNase I), and transfect two DNA plasmids with different
characteristics into COS-7 cells has been demonstrated, with an
efficiency equal or even superior to that exhibited by the
universal control Lipo2000*, as long as the effective charge
ratio ρeff is maintained low. In addition, under these conditions,
the viability of COS-7 cells was maintained at levels greater
than 80%. Slightly better transfection performances were
obtained at moderate GBA lipid contents in the lipid mixture,
correlated with a better protection of the plasmid from the
degrading action of the DNase I enzyme and the enhanced
mobility of the pDNA−mixed lipid nanostructures at α = 0.5.
In conclusion, C6C22C6/DOPE−pDNA lipoplexes are optimal
candidates for nonviral gene nanocarriers because of their low
toxicity and high biological activity in vitro, being therefore
potentially interesting candidates for in vivo experiments.
■ EXPERIMENTAL SECTION
Materials. 1,22-Bis(hexyl dimethyl ammonium)docosane
(C6C22C6) was synthesized from the corresponding α,α′-
dibromide. 1,22-Dibromodocosane was prepared by Kolbe
electrolysis of 11-bromoundecanoic acid in methanol; 1,22-
dibromodocosane (1.0 g) and anhydrous N,N-dimethyl hexyl
amine (0.83 mL) in 50 mL of acetone were boiled under reflux
for 96 h. The material obtained after removal of the solvent
with a rotary evaporator was crystallized from ethanol−ether.
The obtained crystals were then dried in a vacuum desiccator at
ambient temperature to give the desired product (25% yield).
1H NMR (300 MHz, D2O, 25 °C): δ = 3.28 (m, 8H), δ = 3.11
(s, 12H), δ = 1.69 (brs, 8H), δ = 1.43−1.23 (m, 48H) and δ =
0.92 (m, 6H). MS (ESI): m/z calculated for [6-22-62+]2+,
283.83; found, 283.829; calculated for [6-22-62+ Br−]+, 645.57;
found, 645.579. The zwitterionic lipid DOPE was purchased
with highest purity from Avanti Polar Lipids, Inc., Alabaster,
USA. The sodium salt of calf thymus DNA (ctDNA), as
provided by Sigma-Aldrich (St. Louis, USA), was used as linear
DNA to determine the effective charge of the GBA cationic
vector (C6C22C6). The pEGFP-C3 plasmid DNA (4700 bp)
encoding the GFP was extracted from competent Escherichia
coli bacteria previously transformed with pEGFP-C3. The
extraction was carried out using a GenElute HP Select Plasmid
Gigaprep kit (Sigma-Aldrich). The pCMV-Luc VR1216
plasmid DNA (6934 bp) encoding luciferase (Clontech, Palo
Alto, USA) was amplified in E. coli and isolated and purified
using a QIAGEN Plasmid Giga kit (QIAGEN GMBH, Hilden,
Germany). All reagents and solvents were of the highest grade
commercially available and used without further purification.
Preparation of Lipoplexes. Appropriate amounts of
C6C22C6 and DOPE were dissolved in chloroform to obtain
the desired molar compositions of the cationic lipid (α) in the
lipid mixtures. After briefly vortexing the corresponding
solutions, the solvent was removed to yield dry lipid films.
The resulting dry lipid films were then hydrated with 40 mM
HEPES (pH 7.4) and homogenized by means of a combination
of vortexing and sonication. By a sequential extrusion
procedure explained in detail elsewhere,45,51 the multilamellar
liposomes were transformed into the desired unilamellar ones.
Appropriate amounts of a stock solution of pDNA prepared the
day before were added to lipid suspensions to obtain the
lipoplexes. pDNA concentrations were chosen to fit the
optimum conditions for each experimental technique as
follows: 1 mg/mL for zeta potential, 1 mg/mL for cryo-
TEM, 200 μg/capillary (∼5 mg/mL) for SAXS, and 1 μg/well
(2 μg/mL) for biological studies.
Zeta Potential and Particle Size. The phase analysis light
scattering technique (Zeta PALS, Brookhaven Instruments
Corp., Holtsville, USA) was employed to measure the
electrophoretic mobility, which was then used to obtain the
zeta potential of the nanoaggregates. The particle size was
determined by a DLS method using a particle analyzer (Zeta
Nano Series; Malvern Instruments, Barcelona, Spain). In both
studies, samples were prepared with 40 mM HEPES buffer (pH
7.4) under experimental conditions of 25 °C, dispersant
refractive index of 1.33 (water), viscosity of 0.9 cP, and
dispersant dielectric constant of 78.5. Each zeta potential and
particle size data point was taken as the average of 50 and 30
independent measurements, respectively. Measurements were
carried out as a function of total lipid/DNA mass ratio ((mL+ +
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mL0)/mDNA) and at different molar fractions (α) of the cationic
lipid in the GBA/DOPE mixed lipids.
Gel Electrophoresis. DNA Compaction Assay. Lipoplexes
along with uncomplexed pDNA were loaded on 1% agarose
gels (with 0.7 μL of GelRed) and run for 30 min at 80 mV in
1× TAE buffer. Fully complexed lipoplexes appeared as a
fluorescence band in the wells of the gel, whereas uncomplexed
pDNA appeared outside the wells. The fluorescence spectros-
copy conditions were excitation at 302−312 nm and emission
at 600 nm. The fluorescence intensity of each band was
measured using the commercial Quantity One software and a
Gel Doc XR instrument (Bio-Rad).
DNA Protection Assay. DNase I (1 U/μg pDNA) was added
to each mixed lipid sample and stirred for 30 min at 37 °C.
Then, 20 μL of 0.25 M EDTA was added to inactive DNase I,
and the samples were incubated for 15 min. Next, 15 μL of 25%
SDS was added and incubated for 5 min. Samples were
electrophoresed for 40 min under 80 mV in 1% agarose gel
with 1 μL of EtBr. The fluorescence spectroscopy conditions
were excitation at 482 nm and emission at 616 nm. The
integrity of the plasmid at each composition was compared with
that of the untreated DNA as a control.
Small-Angle X-Ray Scattering. SAXS experiments were
carried out on a beamline NCD11 at the ALBA Synchrotron
(Barcelona, Spain). The energy of the incident beam was 12.6
keV (λ = 0.995 Å). Samples were placed in sealed glass
capillaries. The scattered X-rays were detected on a Quantum
210r CCD detector, converted to one-dimensional scattering
by radial averaging, and represented as a function of
momentum transfer vector. SAXS experiments were performed
for C6C22C6/DOPE−pDNA lipoplexes at an effective charge
ratio (GBA lipid/DNA) of ρeff = 4 and at several cationic lipid
compositions of the mixed lipids, α = 0.2, 0.4, 0.5, and 0.7.
Measurements for each composition were run in duplicate in
two independent capillaries.
Cryo-TEM. Cryo-TEM experiments were carried out
following the standard procedure.53−55 In these experiments,
perforated Quantifoil R1.2/1.3 (a hole diameter of 1.2 μm) on
a 400-mesh copper grid was used. The images were obtained
using a JEOL JEM 2011 cryo-electron microscope operated at
200 kV under low-dose conditions and using different degrees
of defocus (500−700 nm) to obtain the adequate phase
contrast. Images were recorded with a Gatan 794 Multiscan
digital camera. Finally, the CCD images were processed and
analyzed with DigitalMicrograph. Cryo-TEM experiments were
performed with C6C22C6/DOPE−pDNA lipoplexes at ρeff = 4
and at two cationic lipid compositions in the mixed lipid, α =
0.2 and 0.5.
Atomic Force Microscopy. Supported planar bilayers for
AFM experiments were prepared as follows: 60 μL of a mixed
lipid sample with the desired composition in 40 mM HEPES
(pH 7.4) was incubated at 37 °C for 45 min on a freshly
cleaved mica surface to ensure liposome extension and
subsequent formation of an SLB. After this period, the sample
was gently rinsed with buffer to eliminate all nonadsorbed
mixed lipids and mounted immediately on the top of the AFM
scanner. A minimum of 30 min was required to stabilize the
sample in the liquid to minimize any drift effects during
scanning. AFM intermittent contact mode images in liquid at
24.0 ± 0.2 °C were obtained using a commercial NanoScope IV
MultiMode microscope (Bruker, AXS Corporation, Madison,
USA) with MSNL-10 silicon tips with a nominal spring
constant of 30 pN/nm. The individual spring constants of the
cantilevers were measured using the thermal tune method,
yielding values similar to the nominal spring constant value.
During scanning, the vertical force was maintained at the
minimum value, maximizing the amplitude set point value while
keeping the vibration amplitude as low as possible. Images were
scanned at a scan angle of 0° and a scan rate of 1.5 Hz. After
injection of a pDNA solution (0.1 μg/μL) and scanning of the
first image, the tip was retracted from the surface of the sample
until the next image was obtained to exclude side effects due to
the proximity of the tip to the SLB. All images were processed
by the NanoScope Analysis software (Bruker AXS Corporation,
Santa Barbara, USA).
Cell Culture. COS-7 (African green monkey kidney) cells
(American Type Collection, Rockville, USA) were maintained
at 37 °C under 5% CO2 in a complete medium constituted by
Dulbecco’s modified Eagle mediumhigh glucose + Gluta-
MAX (Gibco BRL Life Technologies) supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100
U/mL), and streptomycin (100 μg/mL).
In Vitro TE. Two methods were used to evaluate the TE:
luminometry for the pDNA encoding luciferase and FACS for
the pDNA encoding the GFP. In both methods, each
measurement was carried out in triplicate in three wells from
three independent cultures. Lipofectamine (Lipo2000*) was
used as the positive control (1.5 μL of Lipo2000*/μg of DNA).
Luminometry. Cells were seeded in a complete medium in
48-well plates and incubated for 24 h at 37 °C in 5% CO2. The
medium was then removed, and 0.3 mL of the same medium
and 0.2 mL of the complexes were added to each well. After 4 h
of incubation, the medium was replaced by a complete medium
and the cells were further incubated for 48 h in a medium
containing 10% FBS. The cells were washed with phosphate-
buffered saline (PBS) and lysate with 100 μL of reporter lysis
buffer (Promega, Madison, USA) at room temperature for 10
min, followed by two freeze−thaw cycles. The lysate cells were
centrifuged for 2 min at 12 000g to pellet the debris. Then, 20
μL of the supernatant was assayed for total luciferase activity
using the luciferase assay reagent (Promega). A luminometer
(Sirius-2, Berthold Detection Systems, Innogenetics, Diagnoś-
tica y Terapeútica, Barcelona, Spain) was used to measure the
luciferase activity. The protein content of the lysates was
measured by the DC protein assay reagent (Bio-Rad, Hercules,
CA, USA) using bovine serum albumin as the standard. Data
are expressed as nanograms of luciferase per milligrams of
protein.
Fluorescence-Assisted Cell Sorting. Cells were seeded in a
medium in 48-well plates and incubated for 24 h at 37 °C in 5%
CO2. The medium was removed, and 200 μL of trypsin (1×)
was added to each well. After 2 min of incubation at 37 °C, 400
μL of complete medium was added to neutralize the trypsin.
The samples were transferred to cytometer tubes and
centrifuged for 5 min at 1450 rpm and 4 °C. Finally, the
pellets were resuspended in 500 μL of a buffer containing PBS
with 0.5% BSA and 2.5 mM EDTA. Then, cells were sorted
using a flow cytometer. FACS analysis was performed using a
Calibur 345 cytometer equipped with a 488 nm laser and the
BD CellQuest Pro software. The cells were first gated using a
forward scatter versus side scatter strategy to exclude any debris
(low events) and then specifically analyzed by their 530 nm
emission (FL1-H channel; the axis FL1-H shows the relative
intensity of the GFP fluorescence). The data were analyzed
using the FlowJo LLC data software. TEs were quantified by
means of the percentage of GFP cells, that is, the percentage of
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cells in which GFP expression was observed, and the average
intensity of fluorescence per cell (MFI).
Cell Viability. The cell viability was quantified by a modified
alamarBlue assay. Briefly, 1 mL of 10% (v/v) alamarBlue dye in
Dulbecco’s modified Eagle medium, supplemented with 10%
(v/v) FBS medium, was added to each well 48 h after
transfection. After 2 h of incubation at 37 °C, 200 μL of the
supernatant was assayed by measuring the absorbance at 570
and 600 nm. Wells containing medium and alamarBlue dye
without cells were used as blanks. The cell viability was
calculated according to the following formula: (A570 −
A600)treated cells × 100/(A570 − A600)control cells. Each sample was
measured in three independent wells, and Lipo2000* was used
as the positive control (1.5 μL of Lipo2000*/μg of DNA).
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Drechsler, M.; Štep̌ańek, P.; Couvreur, P.; Lesieur, S. DNA/Fusogenic
Lipid Nanocarrier Assembly: Millisecond Structural Dynamics. J. Phys.
Chem. Lett. 2013, 4, 1959−1964.
(21) Angelova, A.; Garamus, V. M.; Angelov, B.; Tian, Z.; Li, Y.; Zou,
A. Advances in structural design of lipid-based nanoparticle carriers for
delivery of macromolecular drugs, phytochemicals and anti-tumor
agents. Adv. Colloid Interface Sci. 2017, 249, 331.
ACS Omega Article
DOI: 10.1021/acsomega.7b01657
ACS Omega 2018, 3, 208−217
216
(22) Niculescu-Duvaz, D.; Heyes, J.; Springer, C. Structure-activity
relationship in cationic lipid mediated gene transfection. Curr. Med.
Chem. 2003, 10, 1233−1261.
(23) Ahmed, T.; Kamel, A. O.; Wettig, S. D. Interactions between
DNA and Gemini surfactant: impact on gene therapy: part I.
Nanomedicine 2016, 11, 289−306.
(24) Zhi, D.; Zhang, S.; Cui, S.; Zhao, Y.; Wang, Y.; Zhao, D. The
headgroup evolution of cationic lipids for gene delivery. Bioconjugate
Chem. 2013, 24, 487−519.
(25) Meister, A.; Blume, A. Self-assembly of bipolar amphiphiles.
Curr. Opin. Colloid Interface Sci. 2007, 12, 138−147.
(26) Mamusa, M.; Resta, C.; Barbero, F.; Carta, D.; Codoni, D.;
Hatzixanthis, K.; McArthur, M.; Berti, D. Interaction between a
cationic bolaamphiphile and DNA: The route towards nanovectors for
oligonucleotide antimicrobials. Colloids Surf., B 2016, 143, 139−147.
(27) Fuhrhop, J. H.; Fritsch, D. Bolaamphiphiles form ultrathin,
porous and unsymmetric monolayer lipid membranes. Acc. Chem. Res.
1986, 19, 130−137.
(28) Fuhrhop, J. H.; Wang, T. Bolaamphiphiles. Chem. Rev. 2004,
104, 2901−2938.
(29) Mao, G.; Tsao, Y.-H.; Tirrell, M.; Davis, H. T.; Hessel, V.; van
Esch, J.; Ringsdorf, H. Monolayers of bolaform amphiphiles: Influence
of alkyl chain length and counterions. Langmuir 1994, 10, 4174−4184.
(30) Philosof-Mazor, L.; Dakwar, G. R.; Popov, M.; Kolusheva, S.;
Shames, A.; Linder, C.; Greenberg, S.; Heldman, E.; Stepensky, D.;
Jelinek, R. Bolaamphiphilic vesicles encapsulating iron oxide nano-
particles: New vehicles for magnetically targeted drug delivery. Int. J.
Pharm. 2013, 450, 241−249.
(31) Popov, M.; Hammad, I. A.; Bachar, T.; Grinberg, S.; Linder, C.;
Stepensky, D.; Heldman, E. Delivery of analgesic peptides to the brain
by nano-sized bolaamphiphilic vesicles made of monolayer mem-
branes. Eur. J. Pharm. Biopharm. 2013, 85, 381−389.
(32) Hwang, S. R.; Kim, K. Nano-enabled delivery systems across the
blood−brain barrier. Arch. Pharmacal Res. 2014, 37, 24−30.
(33) Fariya, M.; Jain, A.; Dhawan, V.; Shah, S.; Nagarsenker, M. S.
Bolaamphiphiles: a pharmaceutical review. Adv. Pharm. Bull. 2014, 4,
483−491.
(34) Zana, R. Bolaform and dimeric (gemini) surfactants. Specialist
Surfactants; Springer, 1997; pp 81−103.
(35) Akhtar, S.; Benter, I. Toxicogenomics of non-viral drug delivery
systems for RNAi: Potential impact on siRNA-mediated gene silencing
activity and specificity. Adv. Drug Delivery Rev. 2007, 59, 164−182.
(36) Denoyelle, S.; Polidori, A.; Brunelle, M.; Vuillaume, P. Y.;
Laurent, S.; ElAzhary, Y.; Pucci, B. Synthesis and preliminary biological
studies of hemifluorinated bifunctional bolaamphiphiles designed for
gene delivery. New J. Chem. 2006, 30, 629−646.
(37) Jain, N.; Arntz, Y.; Goldschmidt, V.; Duportail, G.; Meĺy, Y.;
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Carmona, T.; Marcelo, G.; Martínez-Negro, M.; Aicart, E.; Junquera,
E.; Mendicuti, F.; de Ilarduya, C. T.; Mellet, C. O.; Fernańdez, J. M. G.
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